Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
G MEDICAL INNOVATIONS Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TELADOC HEALTH | 7,075 | -2,60 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Hims & Hers, Teladoc & XTI Aerospace) | ||
HIMS & HERS HEALTH | 40,250 | -0,89 % | Best Stocks to Buy: Hims & Hers Stock vs. UnitedHealth Stock | ||
BICO GROUP | 3,274 | -1,92 % | Bico Group Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
GERATHERM MEDICAL | 3,140 | -5,42 % | Geratherm Medical AG: GJ24 war herausfordernd, vorsichtige Prognose für GJ25; mwb research bekräftigt KAUFEN | Die Ergebnisse von Geratherm für das Geschäftsjahr 2024 zeigten einen Umsatzrückgang von 33% auf 14,0?Mio.?EUR, was in erster Linie auf deutliche Rückgänge in den Bereichen Healthcare Diagnostics und... ► Artikel lesen | |
DEXCOM | 70,94 | +0,14 % | IDEXX, DexCom lead S&P 500 healthcare gains in Q2; UnitedHealth and Bristol Myers Squibb among top laggards | ||
NUGEN MEDICAL DEVICES | 0,033 | +3,80 % | NuGen Medical Devices - Lillys Geschichte: Ein Teenager aus Nordkanada… | ||
PLUS THERAPEUTICS | 0,308 | -0,71 % | Plus Therapeutics Inc.: Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases | Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award... ► Artikel lesen | |
HEALWELL AI | 0,862 | +3,86 % | HEALWELL AI gibt Abstimmungsergebnisse der Hauptversammlung 2025 bekannt | TORONTO, ON, 2. Juli 2025 / IRW-Press / HEALWELL AI Inc. ("HEALWELL" oder das "Unternehmen") (TSX:
AIDX) (OTCQX: HWAIF), ein Gesundheitsunternehmen mit Fokus auf Künstliche Intelligenz... ► Artikel lesen | |
ATOSSA THERAPEUTICS | 0,702 | +0,43 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2025 Financial Results | Revenues increased 9% in Q4 2025 compared to Q4 2024, and 12% in FY 2025 compared to FY 2024Net loss improved 27% in Q4 2025 compared to Q4 2024, and 29% in FY 2025 compared to FY 2024EBITDA loss improved... ► Artikel lesen | |
EMEIS | 11,650 | +5,43 % | emeis 2025 Annual General Meeting | Summary of Voting Results
Regulatory News:
emeis (Paris:EMEIS):
Guillaume Pepy, Chairman of the Board of Directors:"Today, we are particularly proud to announce, together with the Board... ► Artikel lesen | |
CYTOSORBENTS | 0,826 | -24,50 % | Cytosorbents Corp: CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR | PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China | Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest... ► Artikel lesen | |
ONTRAK | 0,481 | +13,33 % | Ontrak, Inc. - 8-K, Current Report |